Cooling RF E Light IPL Hair Removal Beauty Machine
Posted on
Model NO.: S300
Theory: IPL
Portable: Portable
Transport Package: Aluminum Case
Origin: China Mainland
Type: Hair Removal Instrument
Application: Salon
Trademark: AURO
Specification: 115*60*60cm
Elight Principle:
 E-light technology is a combination of the advantages of IPL and RF technologies, which makes use of the resistance difference between the target tissue and normal skin resulted from selective absorption effect of the skin to photon energy. The energy of Radio Frequency can reach the middle and deep layer of the skin and heat up tissue, thus, lower energy is applied during the IPL treatment. Uncomfortable feeling during the IPL treatment will be decreased significantly and better result can be expected. In addition, cooling system involved in E-light can also ease the uncomfortable feeling. The absorbing of the energy of radio frequency is not concerned with melanin. So, the E-Light treatment can get good result on the soft or thin hair so as to decrease the risk caused by traditional IPL treatment. Â
Elight Applications:
 1. skin tightening: skin lifting, improve flexibility and skin tone condition 2. skin rejuvenation: wrinkles reduction, pigments, freckles, vascular lesions(telangiectasis) removal, skin whitening, shrink large hair pores. 3. hair removal : all kinds of skin and color(except white hair) 4. acne removal: improve the situation of oily skin, kill acne bacilli. Â
RF Principle
 The heat caused by interaction of RF (Radio Frequency) energy and dermal resistance can reach dermal layer to heat up and stimulate the collagen fibers, making them regenerate and re-arrange, which can help the skin in better condition. Â
RF Application:
 1, Skin Lifting, Skin Tightening, and Skin whitening; 2, Collagen stimulation and generation; 3, Wrinkle and Fine Lines removal; 4, Face and Figure restructuring; 5, Large pore shrinkage Â
Axitinib is a multi-targeted tyrosine kinase inhibitor for the treatment of patients with advanced renal cancer who have not responded to other systemic therapies.
Cas 886230-75-7,Axitinib Intermediates,6-Iodo-1H-Indazole